Actively Recruiting
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer
Led by Peking Union Medical College Hospital · Updated on 2023-04-12
100
Participants Needed
1
Research Sites
365 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in borderline resectable or locally advanced pancreatic cancer. The main questions it aims to answer are: * prognostic value of baseline MRD; * the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood derived from participants will be obtained for MRD test before conversion therapy initiation and at the first imaging assessment after chemotherapy.
CONDITIONS
Official Title
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with histologically confirmed borderline resectable or locally advanced pancreatic cancer
- Conversion therapy was planned
- Both sexes, age 18 years or older
- ECOG performance status score 2 or less
- Expected survival time of at least 3 months
You will not qualify if you...
- Known diagnosis of pancreatic cancer other than ductal adenocarcinoma
- Treated with any systemic antitumor treatment before first-line chemotherapy onset
- Died or lost to follow-up within one month after the start of first-line chemotherapy
- Combined with other primary malignancies
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China, 100032
Actively Recruiting
Research Team
C
Chunmei Bai, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here